Practical Neurology Podcast
Guidelines on disease-modifying treatment in MS: a decade-long update
Mar 26, 2025
Tamara Kaplan, an MS specialist at Harvard Medical School, and Michael Barnett, a consultant neurologist from Sydney, dive deep into the latest guidelines on disease-modifying treatments for multiple sclerosis. They discuss the evolution and importance of these therapies, emphasizing early intervention. The duo also navigates the complexities of individualized treatment approaches, including safety during pregnancy and the challenges posed by varying healthcare systems. Case studies illustrate the necessity for personalized care in MS management, highlighting a global perspective on the issue.
36:05
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The latest guidelines emphasize the necessity of high-efficacy therapies as a first-line treatment for MS to prevent progression.
- Differences in treatment accessibility between the UK and Australia highlight the impact of healthcare systems on MS patient care and clinician decisions.
Deep dives
Understanding Multiple Sclerosis Treatment Guidelines
The discussion revolves around the latest guidance on disease-modifying therapies (DMTs) for multiple sclerosis (MS), emphasizing its role as a valuable resource for neurologists. The guidelines cover critical aspects such as eligibility, initiation, monitoring, switching, and cessation of therapy while also addressing considerations for pregnancy. The importance of this guidance lies in its ability to inform clinical decisions and ensure equitable access to treatment for patients. Both experts expressed their appreciation for the thoroughness of the guidelines, acknowledging that such consensus-based recommendations help tackle key challenges in managing MS.
